A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin

D. L. Cohn; E. J. Fisher; G. T. Peng; J. S. Hodges; J. Chesnut; C. C. Child; B. Franchino; C. L. Gibert; W. El Sadr; R. Hafner; J. Korvick; M. Ropka; L. Heifets; J. Clotfelter; D. Munroe; C. R. Horsburgh

A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin

D. L. Cohn, E. J. Fisher, G. T. Peng, J. S. Hodges, J. Chesnut, C. C. Child, B. Franchino, C. L. Gibert, W. El Sadr, R. Hafner, J. Korvick, M. Ropka, L. Heifets, J. Clotfelter, D. Munroe, C. R. Horsburgh

Mailman School of Public Health

Résultat de recherche › examen par les pairs

Résumé

The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.

Langue d'origine	English
Pages (de-à)	520-521
Nombre de pages	2
Journal	International Journal of Leprosy and Other Mycobacterial Diseases
Volume	67
Numéro de publication	4 SUPPL.
Statut de publication	Published - 1999

ASJC Scopus Subject Areas

Dermatology

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Autres fichiers et liens

Empreinte numérique

Plonger dans les sujets de recherche 'A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin'. Ensemble, ils forment une empreinte numérique unique.

Citer

Cohn, D. L., Fisher, E. J., Peng, G. T., Hodges, J. S., Chesnut, J., Child, C. C., Franchino, B., Gibert, C. L., El Sadr, W., Hafner, R., Korvick, J., Ropka, M., Heifets, L., Clotfelter, J., Munroe, D., & Horsburgh, C. R. (1999). A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. International Journal of Leprosy and Other Mycobacterial Diseases, 67(4 SUPPL.), 520-521.

A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. / Cohn, D. L.; Fisher, E. J.; Peng, G. T. et al.
Dans: International Journal of Leprosy and Other Mycobacterial Diseases, Vol. 67, N° 4 SUPPL., 1999, p. 520-521.

Résultat de recherche › examen par les pairs

Cohn, DL, Fisher, EJ, Peng, GT, Hodges, JS, Chesnut, J, Child, CC, Franchino, B, Gibert, CL, El Sadr, W, Hafner, R, Korvick, J, Ropka, M, Heifets, L, Clotfelter, J, Munroe, D & Horsburgh, CR 1999, 'A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin', International Journal of Leprosy and Other Mycobacterial Diseases, vol. 67, n° 4 SUPPL., pp. 520-521.

Cohn, D. L. ; Fisher, E. J. ; Peng, G. T. et al. / A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients : Excess mortality associated with high-dose clarithromycin. Dans: International Journal of Leprosy and Other Mycobacterial Diseases. 1999 ; Vol. 67, N° 4 SUPPL. pp. 520-521.

@article{362fedde8e494e72a87e246468923c56,

title = "A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin",

abstract = "The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.",

author = "Cohn, {D. L.} and Fisher, {E. J.} and Peng, {G. T.} and Hodges, {J. S.} and J. Chesnut and Child, {C. C.} and B. Franchino and Gibert, {C. L.} and {El Sadr}, W. and R. Hafner and J. Korvick and M. Ropka and L. Heifets and J. Clotfelter and D. Munroe and Horsburgh, {C. R.}",

year = "1999",

language = "English",

volume = "67",

pages = "520--521",

journal = "International Journal of Leprosy and Other Mycobacterial Diseases",

issn = "0148-916X",

publisher = "Allen Press Inc.",

number = "4 SUPPL.",

}

TY - JOUR

T1 - A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients

T2 - Excess mortality associated with high-dose clarithromycin

AU - Cohn, D. L.

AU - Fisher, E. J.

AU - Peng, G. T.

AU - Hodges, J. S.

AU - Chesnut, J.

AU - Child, C. C.

AU - Franchino, B.

AU - Gibert, C. L.

AU - El Sadr, W.

AU - Hafner, R.

AU - Korvick, J.

AU - Ropka, M.

AU - Heifets, L.

AU - Clotfelter, J.

AU - Munroe, D.

AU - Horsburgh, C. R.

PY - 1999

Y1 - 1999

N2 - The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.

AB - The optimal regimen for treatment of Mycobacterium avium complex (MAC) disease has not been established. Eighty-five AIDS patients with disseminated MAC disease were randomized to receive a three-drug regimen of clarithromycin, rifabutin or clofazimine, and ethambutol. Two dosages of clarithromycin, 500 or 1000 mg twice daily (b.i.d.), were compared. The Data and Safety Monitoring Board recommended discontinuation of the clarithromycin dosage comparison and continuation of the rifabutin vs. clofazimine comparison. After a mean follow up of 4.5 months, 10 (22%) of 45 patients receiving clarithromycin at 500 mg b.i.d. had died (70 deaths per 100 person-years) compared with 17 (43%) of 30 patients receiving clarithromycin at 1000 mg b.i.d. (158 deaths per 100 person-years) (relative risk 2.43; 95% confidence interval 1.11-5.34; p = 0.02). After 10.4 months, 20 (49%) of 41 patients receiving rifabutin had died (81 deaths per 100 person-years) compared with 23 (52%) of 44 patients receiving clofazimine (94 deaths per 100 person-years) (relative risk 1.20; 95% confidence interval 0.65-2.19; p = 0.56). Bacteriologic outcomes were similar among treatment groups. In treating MAC disease in AIDS patients, the maximum dose of clarithromycin should be 500 mg b.i.d.

UR - http://www.scopus.com/inward/record.url?scp=33748250462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748250462&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748250462

SN - 0148-916X

VL - 67

SP - 520

EP - 521

JO - International Journal of Leprosy and Other Mycobacterial Diseases

JF - International Journal of Leprosy and Other Mycobacterial Diseases

IS - 4 SUPPL.

ER -